Status:
COMPLETED
Echinocandins Versus Azoles for Candidemia Treatment
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Candidemia
Eligibility:
All Genders
Brief Summary
Candidemia is the most frequent invasive fungal disease in intensive care units (ICUs). It remains a major health concern, considering its attributable mortality up to 40% in critically ill patients. ...
Eligibility Criteria
Inclusion
- Patients who had a diagnosis of candidemia during ICU stay and were treated with echinocandins or azoles
Exclusion
- Patients with neutropenia
- Patients without antifungal treatment
- Patients who received antifungal therapy for more than two days before candidemia diagnosis
- Patients receiving liposomal amphotericin b or multiple antifungal agents as first-line therapy
- Patients who received less than 4 days of antifungal therapy after candidemia diagnosis
Key Trial Info
Start Date :
November 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2019
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT03799172
Start Date
November 1 2018
End Date
September 1 2019
Last Update
March 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon, Hôpital de la Croix-Rousse
Lyon, France, 69004